In vitro expression of activation markers and lymphocyte proliferation in response to interleukin 12: effect of immunosuppressive agents.
Degiannis
D
D
Onassis Cardiac Surgery Center, Molecular Immunopathology and Histocompatibility Laboratory, Athens, Greece.
Koniavitou
K
K
D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis*; D000943:Antigens, Differentiation / Q000032:analysis / Q000096:biosynthesis*; D015415:Biomarkers; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D018664:Interleukin-12 / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008562:Membrane Glycoproteins; D016853:Muromonab-CD3 / Q000494:pharmacology; D009699:N-Glycosyl Hydrolases / Q000032:analysis / Q000096:biosynthesis*; D011090:Polyenes / Q000494:pharmacology; D020123:Sirolimus
D015703:Antigens, CD; D000943:Antigens, Differentiation; D015415:Biomarkers; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D016853:Muromonab-CD3; D011090:Polyenes; D018664:Interleukin-12; D016572:Cyclosporine; D009699:N-Glycosyl Hydrolases; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D020123:Sirolimus